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Abstract
Immunoparesis (hypogammaglobulinemia) is associated to an unfavorable prognosis in
newly diagnosed Multiple myeloma (MM) patients. However, this finding has not been vali-
dated in an unselected population-based cohort. We analyzed 2558 newly diagnosed MM
patients in the Danish Multiple Myeloma Registry representing the entire MM population in
Denmark from 2005–2013. Two-thousand two hundred and fifty three patients (90%) pre-
sented with reduction below lower normal levels of at least one uninvolved immunoglobulin.
Using multivariable Cox regression we found that high age, high ISS score, high LDH and
IgA MM were associated to both shorter overall survival and progression free survival. Fur-
thermore, bone marrow plasma cell % was associated to short progression free survival.
Immunoparesis had no independent significant effect on OS (HR 0.9 (95%CI: 0.7;1.0; p =
0.12)). Likewise, the number of suppressed immunoglobulins or the relative degree of sup-
pressed uninvolved immunoglobulins from lower normal level (quantitative immunoparesis)
was not associated to OS in the multivariable analysis. However, quantitative immunopar-
esis with at least 25% reduction (from lower normal level) of uninvolved immunoglobulins
was associated to shorter PFS for the entire population. The impact of quantitative immuno-
paresis on PFS was present irrespective of calendar periods 2005–2008 and 2009–2013.
Our population-based study does not confirm that immunoparesis at diagnosis is an
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independent prognostic factor regarding OS. However, quantitative immunoparesis is asso-
ciated to a shorter PFS.
Introduction
Outcome for patients with Multiple Myeloma (MM) is highly variable, which can be related to
specific tumor characteristics, host factors, tumor burden and disease complications[1]. The
International Staging System (ISS) and classification of chromosomal abnormalities are
accepted standards for prognostication in MM and a combination of ISS and FISH abnormali-
ties with plasma LDH levels has recently proven to be a reliable prognostic tool for assessing
survival outcome of newly diagnosed MM patients enrolled in protocols[2–4].
At diagnosis the majority of patients with MM presents with suppression of one or more of
the uninvolved immunoglobulins (immunoparesis)[5]. The pathogenesis behind the suppres-
sion of the polyclonal immunoglobulin production from normal plasma cells (PC) is complex
and studies have reported immune impairment caused by dysregulation of both the normal
T–and B-cell repertoire and of soluble B-cell maturation agent (BCMA) in MM patients[6–
10]. In Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering
Multiple Myeloma (SMM), immunoparesis has been shown to be a prognostic marker for pro-
gression to symptomatic MM. In a Spanish cohort immunoparesis combined with aberrant
PC immune phenotype could predict risk of progression in patients with MGUS and SMM
[11]. Our group has recently confirmed that immunoparesis is an important independent risk
factor for progression from SMM to MM and immunoparesis can together with the M-protein
level stratify patients into 3 risk categories[12]. In symptomatic MM, a Greek multicenter
study has shown that patients with immunoparesis at diagnosis have a significant worse overall
survival (OS) compared to patients with normal uninvolved immunoglobulins[13]. In a sub-
group of the Greek cohort, they found that presence of immunoparesis also shortened the pro-
gression free survival (PFS). However, these findings have not been validated in a population-
based setting. In addition, it is unknown if the prognostic impact is the same for patients
treated with newer anti-myeloma regimens including immunomodulary drugs (IMIDs) and
proteasome inhibitors.
The primary aim of this study was to evaluate the independent prognostic importance of
immunoparesis for OS and PFS in a large population-based cohort using the Danish Multiple
Myeloma Registry (DMMR), which includes information on all MM patients in Denmark
diagnosed since 2005.
Materials and methods
Study population
We analyzed data of 2558 newly diagnosed MM patients in the DMMR from 1 January 2005
to 31 December 2013. All patients but one (total cohort n = 2557) had complete follow up
data for survival and time to first relapse. The DMMR contains data on baseline biochemis-
try (including immunoglobulin levels by standard nephelometry or tubidimetry), treatment
regimens and response to treatment. The content of DMMR has been described in detail pre-
viously[12]. All MM diagnosed patients in DMMR are compared with the National Patient
Registry in Denmark which ensures that no patients are missed[14]. A recent validation of
the DMMR has shown that data are of high quality[15]. During the study period high-dose
melphalan with autologous stem cell transplantation (ASCT) was recommended for all
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transplant-eligible patients <65 years of age and optional for fit patients 65 years. The
induction regimens have changed substantially during the study period. From 2005–2009
the standard induction regimens for transplant-eligible patients outside clinical trials was
based on combinations of cyclophosphamide-dexamethasone (CyDex). A minority of
patients were treated with vincristine, doxorubicin, and dexamethasone (VAD)[16]. The
elderly or transplant-ineligible MM patients were treated with melphalan-prednisolone
(MP) or MP + thalidomide (MPT) during 2005–2009. In 2009 bortezomib in combination
with dexamethasone or cyclophosphamide-dexamethasone (VD or VCD) was introduced as
first line standard induction for transplant-eligible patients in Denmark[16]. For transplant
ineligible patients the first line treatment from 2009–2013 was based on MPT or MPV or
lenalidomide-dexamethasone (Len-Dex). All patients met the 2003 International Myeloma
Working Group (IMWG) criteria for diagnosis[17]. Progressive disease was defined accord-
ing to 2006 IMWG criteria[18]. Immunoparesis was defined qualitatively as one or more of
uninvolved immunoglobulins below the normal levels IgG < 6.1 g/L, IgA < 0.70 g/L and/
or IgM <0.39g/L at time of diagnosis, as described previously[12]. Quantitative immunopar-
esis was defined as a gradual 25–75% reduction in uninvolved immunoglobulins from lower
normal level. All the biochemical analyses were performed by local clinical biochemical labo-
ratories at the different hematological sites. All Danish laboratories are accredited to interna-
tional standards according to General Requirements for the Competence of Testing and
Calibration Laboratories (ISO/IEC 17025:2005).
Statistics
Baseline patient characteristics were described using median, interquartile range (IQR) and
frequencies and percentages for continuous values. Mann–Whitney U test, X2 test and Fisher’s
exact test were used to compare differences between patient characteristics when appropriate.
Cox proportional hazard regression analysis was used to estimate risk factors for overall sur-
vival (OS) and progression free survival (PFS) with hazard ratios (HR) and 95% confidence
intervals (CI). We performed a multivariable Cox regression including immunoparesis and
univariable significant risk factors. We used backward selection to show HR and p-values for
all risk factors after the exclusion of non-significant variables. Survival curves were estimated
using the Kaplan-Meier method.
Statistical analyses were performed using SPSS software version 22.0 (IBM corporation,
Armonk NY, USA) and R version 3.2.3 (R Foundation for Statistical Computing, Vienna, Aus-
tria). This study was approved by the Danish Data Protection Agency (J.no. 2012-58-0004 and
30–1269) and the Danish Patient Safety Authority (J.no. 3-3013-676/1).
Results
Median follow-up for OS was 77 months and 61 months for PFS. Median age at diagnosis was
70 years and the female to male ratio was 0.45 (Table 1). Median bone marrow plasma cell per-
centage (BMPC%) was 31%. Fifty-four percent presented with IgG M-protein, 21% IgA, 15%
with Light Chain Disease (LCD) only and the median M-protein at diagnosis was 2.8 g/dL.
Ninety % presented with immunoparesis of at least one uninvolved immunoglobulin below
normal level; 19% of which had reduction in one uninvolved immunoglobulin and 71% with a
reduction in 2 or more of the uninvolved immunoglobulins. Eighty-one percent of patients
with immunoparesis had at least a 25% reduction in immunoglobulin level from lower normal
limit, 67% with at least 50% reduction and 32% with at least a 75% reduction (Table 1). In the
254 patients without immunoparesis 29 patients (11%) had LCD myeloma.
Immunoparesis as an independent risk factor in Multiple Myeloma
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Table 1. Baseline characteristics for the entire cohort.
MM
(n = 2557)
-Immunoparesis
(n = 254)
+immunoparesis
(n = 2253)
P
Age 70 (62;77)[30;98] 70 (63;77)[30;93] 70 (62;77)[32;98] 0.89
Gender (F/M) 1147 (45%) / 1410 (55%) 84 (33%) / 170 (67%) 1042 (46%)/1211 (54%) <0.0001
BMPC% (n = 2471) 31 (16;51)[0;100] 14 (8;25)[0;100] 35 (20;55)[0;100] <0.0001
P-M-Protein 0.09
IgA 525 (21%) 48 (19%) 472 (21%)
IgG 1376 (54%) 145 (57%) 1211 (54%)
LCD 388 (15%) 29 (11%) 355 (16%)
IgM 12 (<1%) 3 (1%) 8 (<1%)
IgD 17(<1%) 1 (<1%) 16 (2%)
IgE 2(<1%) 0 (0%) 2 (<1%)
More than one 104 (4%) 12 (5%) 92 (4%)
Non-secretory 53 (2%) 9 (4%) 43 (2%)
Unknown 80 (3%) 7 (3%) 54 (2%)
M-Protein konc. (g/dL) n = 2171 2.8(1.2;4.5)[0;17.2] 1.6(0.6;2.9)[0;6.9] 3.0(1.3;4.7)[0;17.2] <0.0001
Urine M-protein 0.019
Unknown 765 (30%) 68 (27%) 668 (30%)
No 623 (24%) 81 (32%) 535 (24%)
Yes 1169 (46%) 105 (41%) 1050 (46%)
If Yes:
Kappa 712 (61%) 65 (62%) 640 (61%) 0.85
Lambda 422 (36%) 36 (34%) 379 (36%) 0.71
Uspecified 52 (4%) 5 (5%) 47 (4%) 0.88
Immunoparesis (Yes/No)
(50 unknown)
2253 (90%) / 254 (10%) - - -
Immunoparesis no of Ig
0 10%(254)
1 19% (460)
2 71%(1734)
Immunoparesis (25–49% below lower normal level) 81% (2067)
Immunoparesis (50–74% below lower normal level) 67% (1673)
Immunoparesis (75% or more below lower normal level) 32% (800)
Beta-2-Microglobulin (mg/l)
n = 2126
4.3 (2.7;6.9)[0;40.8] 2.7 (2.0;4.7)[0.7;30.3] 4.4 (2.8;7.1)[0;40.8] <0.0001
Albumin (g/l)
n = 2433
36 (31;40)[9;100] 39 (33;42)[16;51] 36 (31;40)[9;100] <0.0001
Creatinine (μmol/l) n = 2521 91 (71;141) [30;2000] 85 (70;111)[30;740] 93 (71;146)[33;2000] 0.0005
LDH (U/l) n = 2444 174 (142;220)[0;1683] 171 (145;205)[0;1368] 174 (142;221)[0;1683] 0.53
ISS <0.0001
I 582 (28%) 116 (55%) 465 (25%)
II 760 (36%) 51 (24%) 701 (38%)
III 752 (36%) 45 (21%) 698 (37%)
Unknown 463 42 389
FISH analyses (n = 417)a 417 (16%) 42 (17%) 372 (17%)
t(4,14) 5 (2%) 63 (3%)
t(14,16) 2 (<1%) 15 (<1%)
del 17p 2(<1%) 27 (1%)
First line treatment
(Continued )
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There was no significant age difference between patients with normal uninvolved immuno-
globulin levels and patients with immunoparesis (Table 1). Relatively more female than male
patients presented with immunoparesis (91% vs. 86% respectively). Both baseline median
BMPC% and M-protein level was significantly higher in patients with immunoparesis (BMPC
% IQR 35(20;55) vs. IQR 14(8;25); p<0.0001, and M-protein 3.0g/dL IQR (1.3;4.7) vs. 1.6g/dL
IQR(0.6;2.9); p<0.0001). Furthermore, more patients with immunoparesis were staged ISS
score II and III compared to patients without immunoparesis (38% (ISSII) and 37%(ISSIII) vs.
24%(ISSII) and 21% (ISSIII)). No relevant difference in the prevalence of immunoparesis was
seen among patients treated with ASCT or without ASCT (28% vs. 25%) (Table 1). There were
more patients with immunoparesis who received IMiDs and Bortezomib in first line treatment
compared to patients with no immunoparesis (for Thalidomide 21% vs. 14%, Bortezomib 31%
vs. 24%). We found no significant difference between the number of patients with immuno-
paresis who achieved Complete Response (CR) or Partial response (PR) (to first line treatment)
compared to patients without immunoparesis (Table 1: p = 0.87 and p = 0.45, respectively).
Fluorescence In Situ Hybridization (FISH) was introduced for MM diagnostic workup in a
minority of centers in Denmark prior to 2008 and has not systematically been reported to the
Table 1. (Continued)
MM
(n = 2557)
-Immunoparesis
(n = 254)
+immunoparesis
(n = 2253)
P
Thalidomideb 519 (20%) 36 (14%) 472 (21%)
Lenalidomideb 131 (5%) 10 (4%) 120 (5%)
Bortezomibb 769 (30%) 61 (24%) 702 (31%)
ASCT completed 721 (28%) 63 (25%) 647 (28%)
65 years 615 (85%)
>65 years 106 (6%)
Allo-HST 4 (<1%) 0 4
Cytostaticsb 2087 (82%) 193 (76%) 1860 (83%)
MPb 875(45%) 92 (36%) 768 (34%)
VADb 31 (2%) 1 (<1%) 29 (1%)
CyDexb 671 (34%) 55 (22%) 604 (27%)
Other cytostatic unspecified 382 (20%)
Year of diagnosis 0.14
2005–2008 1097 (43%) 119 (47%) 943 (42%)
2009–2013 1460 (57%) 135 (53%) 1310 (58%)
Response to first line treatment
 CR 436 (17%) 43 (17%) 391 (17%) 0.87
 PR 1489 (60%) 138 (58%) 1331 (61%) 0.45
One patient was excluded from the study due to lack of follow-up data for PFS and OS. P-values indicate tests for comparison of differences between
patients with and without immunoparesis (see text for details). Interquartile range (IQR) for continuous variables is shown in brackets and range in solid
brackets. Percentages (%) for categorical variables are shown in brackets. Immunoparesis = one or more of uninvolved immunoglobulins below the lower
normal levels IgG < 6.1 g/L, IgA < 0.70 g/L and/or IgM <0.39g/L. BMPC% = bone marrow plasma cell %, ASCT = High-dose Melphalan with autologous
stem cell transplantation. Allo-HST = allogeneic stem cell transplantation, MP = Melphalan-prednisone, VAD = vincristine, doxorubicin, and
dexamethasone, Cy-dex = Cyclophosphamide-dexamethasone. CR = Complete Response, PR = Partial Response.
aFISH (Fluorescence in situ hybridization). Only FISH results positive for the adverse abnormalities; t(4;14), t(14;16) and deletion17p (del17p).
bPercentages of specified treatment is related to the total number of patients in each column; n = 2557, n = 254 and n = 2253 respectively. The percentages
do not add up to 100% in each column as patients might have received more than one of the specified treatments.
https://doi.org/10.1371/journal.pone.0188988.t001
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DMMR during the study period. Therefore, FISH data was only available in 16% (n = 417) of
cases (Table 1).
Prognostic factors for overall survival and progression free survival in
Danish Multiple Myeloma patients
A univariable analysis of potential risk factors for OS and PFS was performed for all patients in
the cohort (all data are available in S1 Table). As expected high age (>65 years), increasing
BMPC%, ISS score, creatinine, LDH levels and IgA M-protein significantly reduced the OS.
Quantitative immunoparesis of 25% or 50% reduction (from lower normal level) in unin-
volved immunoglobulin levels was associated to a significant poorer OS (S1 Table). However,
qualitative immunoparesis was not significantly associated to OS in the univariable analysis
(S1 Table, Fig 1). For PFS univariable significant risk factors were high ISS score, creatinine,
LDH and M-protein levels. Both qualitative and quantitative immunoparesis was associated to
a shorter PFS in the univariable analysis (S1 Table, Fig 2). Furthermore, female patients with a
quantitative immunoparesis of 25% reduction (from lower normal level) in uninvolved immu-
noglobulin were significantly associated to worse OS and PFS (S1 Table).
Fig 1. OS for patients with and without qualitative immunoparesis.
https://doi.org/10.1371/journal.pone.0188988.g001
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Independent risk factors for overall survival and progression free survival
Significant risk factors for both OS and PFS in the univariable analysis were included in a
multivariable Cox regression analyses (Tables 2–4). Age, IgA M-protein, ISS score and high
LDH were risk factors for OS in the multivariable analysis (p<0.0001), whereas increasing
BMPC% failed as an independent risk factor for OS (Table 2). Qualitative immunoparesis
was not a significant risk factor for OS in the multivariable analysis (HR 0.9 (95%CI: 0.7;1.0;
p = 0.12).
Using the same multivariable model, we found that high age and ISS score at diagnosis
were significant independent risk factors for PFS (p<0.0001) (Table 3). High baseline LDH,
high BMPC% and IgA MM showed a modest albeit significant association to shorter PFS
(HR 1.2(95%CI: 1.0;1.3; p = 0.018), HR1.1 (95%CI: 1.0;1.1; p = 0.011) and HR 1.2 (1.1;1.4);
p = 0.005 respectively). Furthermore, both qualitative and quantitative immunoparesis was
tested for impact on OS and PFS when adjusting for significant risk factors in the multivari-
able analysis (Table 4): We found no significant association of either quantitative or qualita-
tive immunoparesis to a shorter OS. Qualitative immunoparesis was near significant risk
Fig 2. PFS for patients with quantitative immunoparesis of 25% (from lower normal level) compared to patients
without immunoparesis.
https://doi.org/10.1371/journal.pone.0188988.g002
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Table 2. Multivariable analysis of factors for OS.
Backward selectiona (N = 1996)
HR (95% CI) P value
Age >65 2.3 (2.0;2.6) <0.0001
ISS <0.0001
I
II 1.7 (1.4;1.9) <0.0001
III 2.3 (2.0;2.6) <0.0001
Creatinine (above normal) - -
LDH (above normal) 1.4 (1.2;1.6) <0.0001
BMPC% (cont.) - -
IgA MM 1.3 (1.2;1.5) <0.0001
Immunoparesis - -
https://doi.org/10.1371/journal.pone.0188988.t002
Table 4. Multivariable analysis of both qualitative and quantitative immunoparesis as risk factors for OS and PFS in all patients.
All patients OSa
HR (95% CI)
OS
P
PFSa
HR (95% CI)
PFS
P
Immunoparesis (0 ref,1 vs. 2 Ig)
0 1 0.16 1 0.023
1 0.8 (0.7; 1.0) 0.058 1.0 (0.8; 1.3) 0.71
2 0.9 (0.7; 1.1) 0.24 1.3 (1.0; 1.5) 0.018
Immunoparesis (25–49% below lower normal level) 1.0 (0.9; 1.2) 0.56 1.3 (1.2; 1.6) <0.0001
Immunoparesis (50–74% below lower normal level) 1.0 (0.9; 1.2) 0.65 1.2 (1.1; 1.4) 0.0007
Immunoparesis(75% or more below lower normal level) 0.9 (0.8; 1.1) 0.35 1.2 (1.0; 1.3) 0.010
aHR and p-values for OS and PFS after adjusting for all significant variables (age>65 years, ISS score, LDH levels, IgA MM for OS and age>65 years, ISS
score, LDH, BMPC% and IgA MM for PFS) in a multivariable cox regression model.
LDH = Lactate dehydrogenase, BMPC% = Bone marrow plasma cell %. Cont. = continuous value. Immunoparesis = one or more of uninvolved
immunoglobulins below the lower normal levels IgG < 6.1 g/L, IgA < 0.70 g/L and/or IgM <0.39g/L. Immunoparesis 1 or 2 = one or two of uninvolved
immunoglobulins below the lower normal levels. Immunoparesis 25%, 50% and 75% red = 25% or 50% or 75% reductions of uninvolved immunoglobulins
below the lower normal level.
https://doi.org/10.1371/journal.pone.0188988.t004
Table 3. Multivariable analysis of factors for PFS.
Backward selectiona (N = 1885)
HR (95% CI) P value
Age >65 1.6 (1.5;1.8) <0.0001
ISS <0.0001
I
II 1.4 (1.2; 1.6) <0.0001
III 1.7 (1.5;1.9) <0.0001
Creatinine (above normal) - -
LDH (above normal) 1.2 (1.0;1.3) 0.018
BMPC% (cont.) 1.1 (1.0;1.1) 0.011
IgA MM 1.2 (1.1;1.4) 0.005
M-protein (<3,3) - -
Immunoparesis - -
https://doi.org/10.1371/journal.pone.0188988.t003
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factor for PFS (HR 1.2 (95%CI: 1.0; 1.4; p = 0.054)). However, quantitative immunoparesis
with either 25%, 50% or 75% reduction in uninvolved immunoglobulin levels was significant
after adjusting for all independent risk factors (HR 1.3 (95%CI: 1.2; 1.6; p<0.0001), HR 1.2
(95%CI: 1.1; 1.4; p = 0.007) and HR 1.2 (95%CI: 1.0; 1.3; p = 0.010) respectively). We also
tested the impact of immunoparesis on OS and PFS in different age groups (Table 5).
Patients65 years of age (n = 890) with qualitative immunoparesis had a better survival
compared to patients with no immunoparesis when adjusting for significant prognostic
markers (HR 0.7 (95%CI: 0.5;0,9; p = 0.017), Table 5). The survival advantage was not pres-
ent in patients with a gradual 25% to 75% decrease in uninvolved immunoglobulin levels.
Neither qualitative nor quantitative immunoparesis was associated to a shorter OS of the
older population >65 years (n = 1667) (Table 5). However, immunoparesis in two unin-
volved immunoglobulins and a 25% or 50% reduction in uninvolved immunoglobulin
levels remained significant factors for a shorter PFS for older patients (>65 years) (HR 1.3
(95%CI: 1.0;1.7; p = 0.024), HR 1.4 (95%CI: 1.2;1.7; p = 0.0002) and HR 1.2 (95%CI: 1.1;1.4;
p = 0.005), respectively (Table 5)).
Bortezomib was introduced in standard induction regimens in Denmark in 2009. We ana-
lyzed if there was a difference in the effects of immunoparesis on OS and PFS in patients diag-
nosed from 2005–2008 (n = 804) and 2009–2013 (n = 1183) (S2 Table). For patients >65 years
we found that 25% reduction in uninvolved immunoglobulin was significantly associated to a
shorter PFS irrespective of calendar period 2005–2008 or 2009–2013 (HR 1.4 (95%CI: 1.1;1.9;
p = 0.019) and HR 1.4 (95%CI: 1.1;1.8; p = 0.007) respectively). For patients <65 years we
observed no significant impact on PFS in the different calendar periods.
Table 5. Immunoparesis and association to OS and PFS in different age groups.
 65 (n = 890) OS PFS
HR (95% CI) P HR (95% CI) P
Immunoparesis (Yes <> no) 0.7 (0.5; 0.9) 0.017 1.1 (0.8; 1.6) 0.41
Immunoparesis (0 ref,1 vs. 2 Ig)
0 1 0.064 1 0.69
1 0.7 (0.5; 1.0) 0.072 1.2 (0.8; 1.7) 0.41
2 0.6 (0.5; 0.9) 0.014 1.1 (0.8; 1.6) 0.44
Immunoparesis (25% below lower normal level) 0.9 (0.7; 1.2) 0.49 1.2 (0.9; 1.6) 0.13
Immunoparesis (50% below lower normal level) 0.9 (0.8; 1.2) 0.62 1.2 (1.0; 1.5) 0.061
Immunoparesis (75% below lower normal level) 0.9 (0.7; 1.1) 0.37 1.2 (1.0; 1.4) 0.051
> 65 (n = 1667) OS PFS
HR (95% CI) P HR (95% CI) P
Immunoparesis (Yes <> no) 1.0 (0.8; 1.2) 0.77 1.2 (1.0; 1.5) 0.10
Immunoparesis (0 ref,1 vs. 2 Ig)
0 1 0.16 1 0.0007
1 0.8 (0.7; 1.1) 0.22 1.0 (0.7; 1.3) 0.86
2 1.0 (0.8; 1.3) 0.98 1.3 (1.0; 1.7) 0.024
Immunoparesis (25% below lower normal level) 1.1 (0.9; 1.3) 0.25 1.4 (1.2; 1.7) 0.0002
Immunoparesis (50% below lower normal level) 1.1 (0.9; 1.2) 0.38 1.2 (1.1; 1.4) 0.005
Immunoparesis (75% below lower normal level) 1.0 (0.8; 1.1) 0.60 1.1 (1.0; 1.3) 0.092
HR and p-values represents values when adjusting for independent risk factors for OS and PFS shown in Tables 2 and 3. Immunoparesis = one or more of
uninvolved immunoglobulins below the reference levels IgG < 6.1 g/L, IgA < 0.70 g/L and/or IgM <0.39g/L. Immunoparesis 1 vs. 2 Ig = 1 or 2 uninvolved
immunoglobulins below reference level.
https://doi.org/10.1371/journal.pone.0188988.t005
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Discussion
This is the first population-based retrospective cohort study of immunoparesis as an indepen-
dent risk factor for OS and PFS in symptomatic multiple myeloma. A multivariable analysis
showed that high age, ISS score, high LDH and IgA subtype were associated to shorter OS and
PFS. Furthermore, high BMPC% was associated to shorter PFS. Surprisingly, immunoparesis
defined qualitatively as one or more uninvolved immunoglobulins below lower normal level
or quantitatively had no significant effect on OS when adjusting for all other significant prog-
nostic markers available in our cohort (Table 2 and Fig 1). Importantly, we found that quanti-
tative immunoparesis (with at least 25%, 50% or 75% immunoglobulin reduction) remained a
significant independent risk factor for PFS in the entire population in a multivariable analysis
(Table 4 and Fig 2).
Our results regarding OS are in disagreement with the findings in a large Greek multicenter
study[13]. Here the authors found that patients with no immunoparesis had significantly
improved survival when adjusting for other prognostic factors. The survival benefit for
patients without immunoparesis was 55 months vs. 41.5 months for patients with immunopar-
esis[13]. In a subgroup analysis from a single center the authors also showed that immunopar-
esis was an independent marker for shorter PFS[13]. Another retrospective study showed
improved OS and PFS in patients without immunoparesis at diagnosis in patients treated in
Medical Research Council (MRC) MM clinical trials from 1980–1997[19]. There are important
differences between our study, the Greek study and the MRC trials. The incidence of immuno-
paresis in the Greek study is comparable to our study (87% vs. 90%), however, in the Greek
study patients were included over a 22 year (1990–2012) period thus before and after the intro-
duction of novel anti-myeloma drugs. The authors found that immunoparesis was associated
to a poorer OS in a multivariable analysis including treatment with IMIDs or Bortezomib
upfront[13]. However, since only 38% of patients in the Greek study received IMIDs or Borte-
zomib the multivariable analysis could only have been performed in a subset of their cohort,
which is not specified by the authors[13]. Also, it is not clear how many patients where
included in the most recent calendar period of their study where novel agents may have been
used in both first line treatment and in the relapse setting. Furthermore, novel agents were not
shown to be independent markers for PFS in the multivariable analysis including immunopar-
esis[13]. The MRC study was based on survival data from studies before the introduction of
novel agents, and patients had arguably a different outcome in OS and PFS than our cohort
[19]. Furthermore, it is not clear whether the prevalence of immunoparesis in the MRC data is
comparable to our study and the Greek study[19]. In a recent Turkish single-center study of
137 newly diagnosed MM patients from 2003–2015, the prognostic importance of immuno-
paresis at diagnosis has been analyzed[20]. In line with our study, the authors could not find a
significant association of immunoparesis with OS in patients treated with novel regimens[20].
Our multivariable analysis included all significant univariable risk factors for both PFS and OS
with a limited degree of missing data. Furthermore, to our knowledge, our study is the first to
investigate the impact of both qualitative and quantitative immunoparesis in a multivariable
analysis and we found no association to poorer OS for either of the definitions. We therefore
do not find evidence that immunoparesis represents a proxy for disease burden nor serve a
marker for aggressive MM. Age was the most influential risk factor for both OS and PFS in our
cohort. We therefore analyzed if there were major differences in the prognostic effect of immu-
noparesis in ages below 65 and above 65 years. For the younger population (65 years) we
found that immunoparesis was actually associated to a slightly better survival when adjusted
for all significant risk factors (Table 5). This small survival benefit seems paradoxical as we
would expect patients with immunoparesis to be more prone to infections which has been
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described as one of the most important risk factors for early death irrespective of patient age
[21]. We do not have data on infections, causes of death nor complete information to assess
other prognostic features such as high-risk FISH, which could explain this finding. In the older
population (>65 years) there was no significant effect of immunoparesis on OS (Table 5). In a
previous study of transplant in-eligible MM patients in Denmark (the vast majority being >65
years old) our group found that infections are the leading cause of early deaths [22]. Signifi-
cantly more patients with immunoparesis died within the first 180 days compaired to patients
alive after 180 days[22]. However, immunoparesis was not evaluated as an independent risk
factor for infections [22].
Most studies define immunoparesis in MM qualitatively; as any of the uninvolved immuno-
globulins below the lower normal level[13,23–25]. Using this definition, we could only find a
trend towards immunoparesis as a predictor of a short PFS. However, a quantitative suppres-
sion in uninvolved immunoglobulins had a significant impact on PFS, also after adjusting for
other significant variables. A significant increased HR for poorer PFS was found when patients
had a reduction in 2 uninvolved immunoglobulins.
Furthermore, we found the 25% reduction in uninvolved immunoglobulin to be signifi-
cantly associated to shorter PFS for patients > 65 years after adjusting for calendar periods
both before and after 2009 where major changes in induction regimens were made (S2 Table).
Interestingly, female MM patients with at least 25% immunoglobulin reduction (but not
minor reductions in normal immunoglobulins) were associated to adverse OS and PFS in the
univariable analysis (S2 Table). Whether a difference in reference interval for healthy men
and women [26] can influence the rate of immunoparesis among male and female myeloma
patients is unknown. A shorter PFS in patients with immunoparesis might be attributed to the
changes in the distribution of normal vs. clonal plasma cells in the BM. Paiva et al. has shown
that patients with>5% polyclonal PCs have a better PFS [27]. However, the authors did not
analyze if there were a direct correlation of polyclonal PCs with the degree of immunoparesis.
We argue that a clinical relevant level of immunoparesis for symptomatic MM should be at
least 25% reduction in one or more uninvolved immunoglobulins.
There are several strengths to our study. In the Danish Health Care System all MM patients
are diagnosed, treated and followed in public hospitals with hematological expertise. This
ensures that our cohort consists of unselected patients and that data represents the entire Dan-
ish Multiple Myeloma population. The complete follow-up data in the DMMR provides a
unique opportunity to evaluate the epidemiology and prognostic features of immunoparesis
and other common MM characteristics in a population-based setting. All laboratories that pro-
vide data for the DMMR are regulated under the same international standards.
There are some limitations to our study. The treatment data registered in the DMMR refers
to whether the patients at some point in the first line treatment received the given drug, but
not in which specific treatment protocol the drug was used. Like other studies, we have no
data on how many patients received immunoglobulin substitution therapy or whether this
replacement therapy could influence the effects of immunoparesis at diagnosis. However, the
treatment guidelines for newly diagnosed and relapse or refractory MM patients in Denmark
are based on national consensus recommendations which are updated annually by the Danish
Myeloma Study Group[28]. Immunoglobulin substitution therapy is generally not part of rou-
tine practice in Danish Myeloma centers regardless of immunoparesis status. Furthermore,
risk stratification using FISH, was only available for a subgroup of our patients. Therefore, the
prognostic effect of immunoparesis could not be evaluated independently of high-risk FISH
status.
In conclusion our populations-based study shows that immunoparesis at diagnosis is not
an independent prognostic factor regarding OS. The data suggests that immunoparesis with at
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least 25% reduction in uninvolved immunoglobulins at the time of diagnosis can identify
patients with a shorter PFS. Further investigation of the consequences of immunoparesis and
other secondary immune defects including the risk of infections, early deaths and/or progres-
sion in symptomatic Multiple Myeloma patients is needed.
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